Galantamine: A Review Update

β-Amyloid1–42 Binds to α7 Nicotinic Acetylcholine Receptor with High Affinity

Wang, H.-Y., Lee, D. H. S., D’Andrea, M. R., Peterson, P. A., Shank, R. P., & Reitz, A. B. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5626 · Cited by 818 · see citing works

APP mouse models for Alzheimer’s disease preclinical studies.

Sasaguri, H., Nilsson, P., Hashimoto, S., Nagata, K., Saito, T., De Strooper, B., Hardy, J., Vassar, R., Winblad, B., & Saido, T. C. (2017) · The EMBO Journal · doi:10.15252/embj.201797397 · Cited by 793 · see citing works

The Evolution of Preclinical Alzheimer’s Disease: Implications for Prevention Trials

Sperling, R., Mormino, E., & Johnson, K. (2014) · Neuron · doi:10.1016/j.neuron.2014.10.038 · Cited by 725 · see citing works

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease

Feldman, H., Gauthier, S. G., Hecker, J., Vellas, B. J., Subbiah, P., Whalen, E., & the Donepezil MSAD Study Investigators Group* (2001) · Neurology · doi:10.1212/wnl.57.4.613 · Cited by 600 · see citing works

Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis

Hansen, R. A., Webb, A. P., Moore, C. G., Gartlehner, G., Jonas, D. E., & Morgan, L. C. (2020) · PubMed Central · doi:10.17615/ae8c-2p76 · Cited by 523 · see citing works

To: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease

(2001) · Neurology · doi:10.1212/wnl.57.11.2153-a · Cited by 490 · see citing works

Brain acetylcholinesterase activity controls systemic cytokine levels through the cholinergic anti-inflammatory pathway

Pavlov, V. A., Parrish, W. R., Rosas‐Ballina, M., Ochani, M., Gallowitsch‐Puerta, M., Ochani, K., Chavan, S. S., Al‐Abed, Y., & Tracey, K. J. (2008) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2008.06.011 · Cited by 437 · see citing works

Galantamine

Scott, L. J., & Goa, K. L. (2000) · Drugs · doi:10.2165/00003495-200060050-00008 · Cited by 383 · see citing works

Structure of acetylcholinesterase complexed with (−)‐galanthamine at 2.3 Å resolution

Greenblatt, H. M., Kryger, G., Lewis, T., Silman, I., & Sussman, J. L. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01637-3 · Cited by 312 · see citing works

Galantamine — a Novel Cholinergic Drug with a Unique Dual Mode of Action for the Treatment of Patients with Alzheimer's Disease

Lilienfeld, S. (2002) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2002.tb00221.x · Cited by 309 · see citing works

Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial

Rockwood, K. J. (2001) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.71.5.589 · Cited by 277 · see citing works

88. A new reaction of hydrazones

Barton, D. H. R., O'Brien, R. E., & Sternhell, S. (1962) · Journal of the Chemical Society (Resumed) · doi:10.1039/jr9620000470 · Cited by 219 · see citing works

Galantamine for Alzheimer's disease

Loy, C. T., & Schneider, L. S. S. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001747.pub2 · Cited by 178 · see citing works

Central nicotinic receptors, neurotrophic factors and neuroprotection

Belluardo, N., Mudò, G., Blum, M., & Fuxé, K. (2000) · Behavioural Brain Research · doi:10.1016/s0166-4328(00)00197-2 · Cited by 176 · see citing works

153. Phenol oxidation and biosynthesis. Part V. The synthesis of galanthamine

Barton, D. H. R., & KIRBY, G. W. (1962) · Journal of the Chemical Society (Resumed) · doi:10.1039/jr9620000806 · Cited by 140 · see citing works

The intramolecular Heck reaction

Gibson, S. E., & Middleton, R. J. (1996) · Contemporary Organic Synthesis · doi:10.1039/co9960300447 · Cited by 138 · see citing works

Galantamine hydrobromide: An agent for Alzheimer’s disease

Zarotsky, V., Sramek, J. J., & Cutler, N. R. (2003) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/60.5.446 · Cited by 136 · see citing works

Nicotinic α7 receptors protect against glutamate neurotoxicity and neuronal ischemic damage

Shimohama, S., Greenwald, D. L., Shafron, D. H., et al. (1998) · Brain Research · doi:10.1016/s0006-8993(97)00194-7 · Cited by 135 · see citing works

Clinical Pharmacokinetics of Galantamine

Farlow, M. R. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342150-00005 · Cited by 134 · see citing works

Activation of Wnt/β-Catenin Signaling Increases Insulin Sensitivity through a Reciprocal Regulation of Wnt10b and SREBP-1c in Skeletal Muscle Cells

Abiola, M., Favier, M., Christodoulou‐Vafeiadou, E., Pichard, A., Martelly, I., & Guillet-Deniau, I. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008509 · Cited by 124 · see citing works

Galantamine modulates nicotinic receptor and blocks Aβ-enhanced glutamate toxicity

Kihara, T., Sawada, H., Nakamizo, T., Kanki, R., Yamashita, H., Maelicke, A., & Shimohama, S. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.10.132 · Cited by 124 · see citing works

Differential diagnosis of Alzheimer's disease

Geldmacher, D. S., & Whitehouse, P. J. (1997) · Neurology · doi:10.1212/wnl.48.5_suppl_6.2s · Cited by 122 · see citing works

Galantamine Alleviates Inflammation and Other Obesity-Associated Complications in High-Fat Diet-Fed Mice

Satapathy, S. K., Ochani, M., Dancho, M. E., Hudson, L., Rosas‐Ballina, M., Valdés‐Ferrer, S. I., Olofsson, P. S., Harris, Y., Roth, J., Chavan, S. S., et al. (2011) · Molecular Medicine · doi:10.2119/molmed.2011.00083 · Cited by 119 · see citing works

Physostigmine, galanthamine and codeine act as ‘noncompetitive nicotinic receptor agonists’ on clonal rat pheochromocytoma cells

Storch, A., Schrattenholz, A. S., Cooper, J. C., Ghani, E. M. A., Gutbrod, O., Weber, K. H., Reinhardt, S., Lobron, C., Hermsen, B., Šoškić, V., et al. (1995) · European Journal of Pharmacology Molecular Pharmacology · doi:10.1016/0922-4106(95)00080-1 · Cited by 117 · see citing works

Galantamine for Alzheimer's disease

Prvulovic, D., Hampel, H. J., & Pantel, J. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425251003592137 · Cited by 110 · see citing works

d-cycloserine attenuates scopolamine-induced learning and memory deficits in rats

Fishkin, R. J., İnce, E., Carlezon, W. A., & Dunn, R. W. (1993) · Behavioral and Neural Biology · doi:10.1016/0163-1047(93)90886-m · Cited by 108 · see citing works

An α7 Nicotinic Acetylcholine Receptor-Selective Agonist Reduces Weight Gain and Metabolic Changes in a Mouse Model of Diabetes

Marrero, M. B., Lucas, R., Salet, C., Hauser, T. A., Mazurov, A. A., Lippiello, P. M., & Bencherif, M. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.154633 · Cited by 105 · see citing works

In vitro neuroprotective properties of the novel cholinergic channel activator (ChCA), ABT-418

Donnelly‐Roberts, D. L., Xue, I. C., Arnerić, S. P., & Sullivan, J. P. (1996) · Brain Research · doi:10.1016/0006-8993(96)00063-7 · Cited by 103 · see citing works

Inhibition of Acetylcholinesterase Activity in Human Brain Tissue and Erythrocytes by Galanthamine, Physostigmine and Tacrine

Thomsen, T., Kaden, B., Fischer, J. P., Bickel, U., Barz, H., Gusztony, G., Cervós‐Navarro, J., & Kewitz, H. (1991) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.1991.29.8.487 · Cited by 92 · see citing works

In vitro effects of various cholinesterase inhibitors on acetyl- and butyrylcholinesterase of healthy volunteers

Thomsen, T., Zendeh, B., Fischer, J. P., & Kewitz, H. (1991) · Biochemical Pharmacology · doi:10.1016/0006-2952(91)90022-w · Cited by 87 · see citing works

Chemical and biological aspects of Amaryllidaceae alkaloids

Armengol, J. B., Berkov, S. H., Torras‐Claveria, L., Pigni, N. B., de Andrade, J. P., Martínez, V., Codina, C., & Meya, F. V. (2011) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) · Cited by 83 · see citing works

Cholinesterase inhibition by galanthamine and lycoramine

Irwin, R. L., & Smith, H. J. (1960) · Biochemical Pharmacology · doi:10.1016/0006-2952(60)90030-7 · Cited by 78 · see citing works

Profiling donepezil template into multipotent hybrids with antioxidant properties

Mezeiová, E., Špilovská, K., Nepovimová, E., Górecki, L., Soukup, O., Doležal, R., Maliňák, D., Janočková, J., Jun, D., Kuča, K., et al. (2018) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2018.1443326 · Cited by 74 · see citing works

Donepezil–Ferulic Acid Hybrids as Anti-Alzheimer Drugs

Benchekroun, M., Ismaïli, L., Pudlo, M., et al. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.14.148 · Cited by 70 · see citing works

Nicotine rescues PC12 cells from death induced by nerve growth factor deprivation

Yamashita, H., & Nakamura, S. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)12829-9 · Cited by 70 · see citing works

Galanthamine, an acetylcholinesterase inhibitor: A time course of the effects on performance and neurochemical parameters in mice

Sweeney, J. E., Puttfarcken, P. S., & Coyle, J. T. (1989) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(89)90364-x · Cited by 67 · see citing works

Galantamine protects against oxidative stress induced by amyloid‐beta peptide in cortical neurons

Melo, J. B., Sousa, C., Garção, P., Oliveira, C. R., & Agostinho, P. M. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2009.06612.x · Cited by 63 · see citing works

Stereoselectivity of cholinesterase inhibition by galanthamine and tolerance in humans

Thomsen, T., Bickel, U., Fischer, J. P., & Kewitz, H. (1990) · European Journal of Clinical Pharmacology · doi:10.1007/bf00316106 · Cited by 62 · see citing works

Indicators of neuroprotection with galantamine

Geerts, H. (2004) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2004.11.002 · Cited by 61 · see citing works

Mechanism of Action of Galantamine on N-Methyl-d-Aspartate Receptors in Rat Cortical Neurons

Moriguchi, S., Marszalec, W., Zhao, X., Yeh, J. Z., & Narahashi, T. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.067603 · Cited by 57 · see citing works

Monoclonal antibodies FK1 and WF6 define two neighboring ligand binding sites on Torpedo acetylcholine receptor alpha-polypeptide.

Schröder, B., Reinhardt-Maelicke, S., Schrattenholz, A. S., McLane, K. E., Kretschmer, A., Conti-Tronconi, B. M., & Maelicke, A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)34075-9 · Cited by 56 · see citing works

Antidiabetic Effect of Galantamine: Novel Effect for a Known Centrally Acting Drug

Ali, M. A., El-Abhar, H. S., Kamel, M. A. E.-N., & Attia, A. S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134648 · Cited by 56 · see citing works

Effects of Donepezil, Galantamine and Rivastigmine in 938 Italian Patients with Alzheimerʼs Disease

Santoro, A., Siviero, P., Minicuci, N., Bellavista, E., Mishto, M., Olivieri, F., Marchegiani, F., Chiamenti, A. M., Benussi, L., Ghidoni, R., et al. (2010) · CNS Drugs · doi:10.2165/11310960-000000000-00000 · Cited by 56 · see citing works

Galantamine is not a positive allosteric modulator of human α4β2 or α7 nicotinic acetylcholine receptors

Kowal, N. M., Ahring, P. K., Liao, V. W. Y., Indurti, D. C., Harvey, B. S., O'Connor, S. M., Chebib, M., Ólafsdóttir, E. S., & Balle, T. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14329 · Cited by 51 · see citing works

Prolonged QT Interval, Syncope, and Delirium with Galantamine

Fisher, A. A., & Davis, M. W. (2008) · Annals of Pharmacotherapy · doi:10.1345/aph.1k514 · Cited by 49 · see citing works

Stimulation of nicotinic acetylcholine receptors protects motor neurons

Nakamizo, T., Kawamata, J., Yamashita, H., Kanki, R., Kihara, T., Sawada, H., Akaike, A., & Shimohama, S. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.115 · Cited by 47 · see citing works

Antioxidant Properties of Galantamine Hydrobromide

Traykova, M., Traykov, T. T., Hadjimitova, V. A., et al. (2003) · Zeitschrift für Naturforschung C · doi:10.1515/znc-2003-5-613 · Cited by 47 · see citing works

Pentacyclo[5.4.0.02,6.03,10.05,9]undecylamines. Synthesis and pharmacology

Dw, O., Dekker, T., & SNYCKERS, F. O. (1991) · European Journal of Medicinal Chemistry · doi:10.1016/0223-5234(91)90097-7 · Cited by 43 · see citing works

A general approach to the galanthamine ring system

Parsons, P. J., Charles, M. D., Harvey, D. M., et al. (2001) · Tetrahedron Letters · doi:10.1016/s0040-4039(01)00111-3 · Cited by 39 · see citing works

Vagus nerve stimulation as a strategy to prevent and manage metabolic syndrome

Das, U. N. (2010) · Medical Hypotheses · doi:10.1016/j.mehy.2010.11.013 · Cited by 35 · see citing works

Current status and new developments with galantamine in the treatment of Alzheimer’s disease

Tariot, P. N. (2001) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2.12.2027 · Cited by 35 · see citing works

Nature’s Anti-Alzheimer’s Drug: Isolation and Structure Elucidation of Galantamine from Leucojum aestivum

Halpin, C. M., Reilly, C., & Walsh, J. J. (2010) · Journal of Chemical Education · doi:10.1021/ed100388x · Cited by 34 · see citing works

A Naturalistic Study of Galantamine for Alzheimer???s Disease

Brodaty, H., Woodward, M., Boundy, K. L., Barnes, N., & Allen, G. (2006) · CNS Drugs · doi:10.2165/00023210-200620110-00006 · Cited by 28 · see citing works

Post hoc comparison of daily rates of nausea and vomiting with once- and twice-daily galantamine from a double-blind, placebo-controlled, parallel-group, 6-month study

Dunbar, F., Zhu, Y., & Brashear, H. R. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.03.002 · Cited by 19 · see citing works

Chemical synthesis of galantamine, an acetylcholinesterase inhibitor for treatment of Alzheimer’s disease

Marco-Contelles, J. L., Rodríguez, C., & Garcı́a, A. G. (2005) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.15.5.575 · Cited by 19 · see citing works

α4 nicotinic acetylcholine receptor modulated by galantamine on nigrostriatal terminals regulates dopamine receptor-mediated rotational behavior

Inden, M., Takata, K., Yanagisawa, D., Ashihara, E., Tooyama, I., Shimohama, S., & Kitamura, Y. (2016) · Neurochemistry International · doi:10.1016/j.neuint.2016.02.008 · Cited by 18 · see citing works

Evaluating the Homeostasis Assessment Model Insulin Resistance and the Cardiac Autonomic System in Bariatric Surgery Patients: A Meta-Analysis

Geronikolou, S. A., Albanopoulos, K., Chrousos, G. P., & Cokkinos, D. V. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-56246-9_20 · Cited by 16 · see citing works

Efficacy and Safety of Incretin Therapy in Type 2 Diabetes: Systematic Review and Meta-analysis

Amori, R. E., Lau, J., & Pittas, A. G. (2007) · JAMA · doi:10.1001/jama.298.2.194 · Cited by 12 · see citing works

Bullous pemphigoid precipitated by galantamine hydrobromide.

Diab, M. S., Coloe, J. R., & Bechtel, M. A. (2009) · PubMed · Cited by 10 · see citing works

A New Stereoselective Approach Towards the Galanthamine Ring System via an Intramolecular Heck Reaction

Pilger, C., Westermann, B., Flörke, U., et al. (2000) · Synlett · doi:10.1055/s-2000-6735 · Cited by 10 · see citing works

Hypothesis: apo‐lactoferrin–Galantamine Proteo‐alkaloid Conjugate for Alzheimer's disease Intervention

Akilo, O. D., Kumar, P., Choonara, Y., Pradeep, P., du Toit, L. D., & Pillay, V. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13484 · Cited by 10 · see citing works

A Review on Pharmacological Potential of Galantamine

Upadhyay, S. D., Ahmad, Y., & Kohli, S. (2020) · Pharmacognosy Communications · doi:10.5530/pc.2020.2.13 · Cited by 9 · see citing works

P4‐009: TRIAL OF OXALOACETATE IN ALZHEIMER'S DISEASE (TOAD): INTERIM FDG PET ANALYSIS

Vidoni, E. D., Clutton, J., Becker, A. M., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.06.2411 · Cited by 4 · see citing works

Cardiac Autonomic Functions in Obese Children - Original Article

Taşçılar, M. E., Yokuşoğlu, M., Boyraz, M., et al. (2011) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.v3i2.13 · Cited by 3 · see citing works

Prospective of managing impaired brain insulin signalling in late onset Alzheimers disease with excisting diabetic drugs

Jojo, G. M., Kuppusamy, G., Selvaraj, K., & Baruah, U. K. (2019) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-019-00405-2 · Cited by 2 · see citing works

Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease

Thawabteh, A. M., Ghanem, A. W., AbuMadi, S., Thaher, D., Jaghama, W., Karaman, D., & Karaman, R. (2024) · Molecules · doi:10.3390/molecules29215131 · Cited by 56 · see citing works

PMH26 A COMPARISON OF TREATMENT PATTERNS AND COSTS FOR SUBJECTS NEWLY TREATED WITH DONEPEZIL VERSUS THOSE NEWLY TREATED WITH GALANTAMINE OR RIVASTIGMINE

Ye, X., Roberts, C., Dl, H., et al. (2009) · Value in Health · doi:10.1016/s1098-3015(10)74745-8

A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis

Harry, R. D., & Zakzanis, K. K. (2005) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.676 · Cited by 25 · see citing works

Donepezil, Rivastigmine and Galantamine: Cholinesterase Inhibitors for Alzheimer's Disease

Sakya, S. M., & Karki, K. (2010) · doi:10.1002/9780470768594.ch17 · Cited by 3 · see citing works

Acetylcholinesterase inhibitors

Rioux, S. (2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.00216-x · Cited by 1 · see citing works

Drugs for cognitive loss and dementia.

Bazil, C. W., Crouse, E. L. B., Dalton, V. K., et al. (2007) · PubMed · Cited by 3 · see citing works